Effects of pregnancy and contraception on lamotrigine disposition: New insights through analysis of lamotrigine metabolites

Seizure

Volumn 17, Issue 2, 2008, Pages 199-202

  Öhman, Inger ^a   Luef, Gerhard ^b   Tomson, Torbjörn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anticonception; Interaction; Lamotrigine; Metabolites; Pharmacokinetics; Pregnancy

Indexed keywords

CLONAZEPAM; LAMOTRIGINE; LAMOTRIGINE 2 N GLUCURONIDE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; TOPIRAMATE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CONTRACEPTION; CONTROLLED STUDY; DRUG ANALYSIS; DRUG EFFECT; DRUG METABOLISM; EPILEPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAUTERINE CONTRACEPTIVE DEVICE CONTAINING LEVONORGESTREL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITE; PARAMETER; PREGNANCY; PRIORITY JOURNAL; URINE;

ADOLESCENT; ADULT; ANTICONVULSANTS; CONTRACEPTION; EPILEPSY; FEMALE; GLUCURONIDES; HUMANS; MIDDLE AGED; PREGNANCY; TRIAZINES;

EID: 38949136345     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2007.11.017     Document Type: Article

References (15)

1. Green M.D., Bishop W.P., and Tephly T.R. Expressed human UGT1A4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 23 (1995) 299-302
2. Beck O., Öhman I., and Nordgren H. Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry. Ther Drug Monit 28 (2006) 603-607
3. Sabers A., Buchholt J.M., Uldall P., and Hansen E.L. Lamotrigine plasma levels reduced by oral contraceptives. Epileps. Res. 47 (2001) 151-154
4. Sabers A., Öhman I., Christensen J., and Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 61 (2003) 570-571
5. Sidhu J., Job S., Singh S., and Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 61 (2006) 191-199
6. Christensen J., Petrenaite V., Atterman J., Sidenius P., Öhman I., Tomson T., et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind placebo-controlled trial. Epilepsia 48 (2007) 484-489
7. Tomson T., Öhman I., and Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 38 (1997) 1039-1041
8. Öhman I., Vitols S., and Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 41 (2000) 709-713
9. Tran T.A., Leppik I.E., Blesi K., Sathanandan S.T., and Remmel R. Lamotrigine clearance during pregnancy. Neurology 59 (2002) 251-255
10. Pennell P.B., Newport D.J., Stowe Z.N., Helmers S.L., Montgomery J.Q., and Henry T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 62 (2004) 292-295
11. de Haan G.J., Edelbroek P., Segers J., Engelsman M., Lindhout D., Dévilé-Notschaele M., et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 63 (2004) 571-573
12. Petrenaite V., Sabers A., and Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epileps. Res. 65 (2005) 185-188
13. Öhman I, Beck O, Vitols S, Tomson T. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy, Epilepsia, in press.
14. Forssblad E., Eriksson A.S., and Beck O. Liquid chromatographic determination of plasma lamotrigine in pediatric samples. J Pharm Biomed Anal 14 (1996) 755-758
15. Reimers A., Helde G., and Brodtkorb E. Ethinyl Estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 46 (2005) 1414-1417